Fig. 1: TRIM21 level was correlated with clinicopathological features and prognosis of CRC patients.
From: TRIM21 promotes colorectal cancer development through regulating DNA replication by TCF3/MCM2/5 axis
A Relative TRIM21 mRNA level in human CRC tissues (n = 98) and normal intestinal epithelium (n = 97) from Cohort 1. **P < 0.01. B Relative TRIM21 mRNA level in human CRC tissues (n = 20) and normal intestinal epithelium (n = 20) from the GSE100179 dataset (left panel). Relative TRIM21 mRNA level in COAD (Tumor, n = 275; Normal, n = 349) and READ (Tumor, n = 92; Normal, n = 318) datasets from GAPIA Database (right panel). *P < 0.05. C Representative IHC staining images and immunoreactive scores of TRIM21 from CRC (n = 87) and adjacent normal tissues (n = 87) in Cohort 2. Scale bars = 100 μm (upper panel) and 25 μm (lower panel). ****P < 0.0001. D Representative IHC staining images and immunoreactive scores of TRIM21 from CRC tissues at different AJCC stages (Stage Ⅰ, n = 5; Stage Ⅱ, n = 53; Stage Ⅲ, n = 35) in Cohort 2. Scale bars = 100 μm (upper panel) and 25 μm (lower panel). *P < 0.05, ns = no significance. E Kaplan–Meier overall survival curves for all CRC patients (n = 93) in Cohort 2 based on TRIM21 level. F Kaplan–Meier overall survival curves for CRC patients aged less than 65 years (left panel, n = 37) and those aged 65 years or more (right panel, n = 56) in Cohort 2 based on TRIM21 level.
